{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:17:26Z","timestamp":1785813446284,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T00:00:00Z","timestamp":1570838400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T00:00:00Z","timestamp":1570838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00198-019-05142-z","type":"journal-article","created":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T18:09:12Z","timestamp":1570903752000},"page":"67-75","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Systematic screening using FRAX\u00ae leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial"],"prefix":"10.1007","volume":"31","author":[{"name":"the SCOOP Trial Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Parsons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Shepstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Kanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lenaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fordham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gittoes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.M.","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.J.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Torgerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.W.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3510-0709","authenticated-orcid":false,"given":"C.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,12]]},"reference":[{"key":"5142_CR1","unstructured":"(1994) World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Geneva"},{"key":"5142_CR2","unstructured":"Kanis JA (2007) Assessment of osteoporosis at the primary health care level. WHO Scientific Group Technical Report. World Health Organization, Geneva"},{"key":"5142_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11657-016-0278-z","volume":"11","author":"JA Kanis","year":"2016","unstructured":"Kanis JA, Harvey NC, Cooper C, Johansson H, Oden A, McCloskey EV (2016) A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 11:25","journal-title":"Arch Osteoporos"},{"key":"5142_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","volume":"12","author":"J Compston","year":"2017","unstructured":"Compston J, Cooper A, Cooper C et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43","journal-title":"Arch Osteoporos"},{"key":"5142_CR5","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1007\/s00198-011-1876-7","volume":"23","author":"L Shepstone","year":"2012","unstructured":"Shepstone L, Fordham R, Lenaghan E, Harvey I, Cooper C, Gittoes N, Heawood A, Peters TJ, O\u2019Neill T, Torgerson D, Holland R, Howe A, Marshall T, Kanis JA, McCloskey E (2012) A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. Osteoporos Int 23:2507\u20132515","journal-title":"Osteoporos Int"},{"key":"5142_CR6","volume-title":"Lancet","author":"L Shepstone","year":"2017","unstructured":"Shepstone L, Lenaghan E, Cooper C et al (2017) Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. In: Lancet"},{"key":"5142_CR7","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/jbmr.3381","volume":"33","author":"DA Turner","year":"2018","unstructured":"Turner DA, Khioe RFS, Shepstone L, Lenaghan E, Cooper C, Gittoes N, Harvey NC, Holland R, Howe A, McCloskey E, O'Neill TW, Torgerson D, Fordham R, the SCOOP Study Team (2018) The cost-effectiveness of screening in the community to reduce osteoporotic fractures in older women in the UK: economic evaluation of the SCOOP study. J Bone Miner Res 33:845\u2013851","journal-title":"J Bone Miner Res"},{"key":"5142_CR8","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/jbmr.3411","volume":"33","author":"E McCloskey","year":"2018","unstructured":"McCloskey E, Johansson H, Harvey NC, Shepstone L, Lenaghan E, Fordham R, Harvey I, Howe A, Cooper C, Clarke S, Gittoes N, Heawood A, Holland R, Marshall T, O'Neill TW, Peters TJ, Redmond N, Torgerson D, Kanis JA, the SCOOP Study Team (2018) Management of patients with high baseline hip fracture risk by FRAX reduces hip fractures-a post hoc analysis of the SCOOP study. J Bone Miner Res 33:1020\u20131026","journal-title":"J Bone Miner Res"},{"key":"5142_CR9","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1002\/jbmr.2301","volume":"29","author":"JA Kanis","year":"2014","unstructured":"Kanis JA, Svedbom A, Harvey N, McCloskey EV (2014) The osteoporosis treatment gap. J Bone Miner Res 29:1926\u20131928","journal-title":"J Bone Miner Res"},{"key":"5142_CR10","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00198-016-3894-y","volume":"28","author":"NC Harvey","year":"2017","unstructured":"Harvey NC, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster JY, Rizzoli R, Cooper C, Kanis JA (2017) Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int 28:1507\u20131529","journal-title":"Osteoporos Int"},{"issue":"3","key":"5142_CR11","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00198-017-3906-6","volume":"28","author":"A. Diez-Perez","year":"2017","unstructured":"Diez-Perez A, Naylor KE, Abrahamsen B, et al. (2017) International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int 28:767\u2013774","journal-title":"Osteoporosis International"},{"key":"5142_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/fampra\/cmr069","volume":"29","author":"CL Emmett","year":"2012","unstructured":"Emmett CL, Redmond NM, Peters TJ, Clarke S, Shepstone L, Lenaghan E, Shaw AR (2012) Acceptability of screening to prevent osteoporotic fractures: a qualitative study with older women. Fam Pract 29:235\u2013242","journal-title":"Fam Pract"},{"issue":"2002","key":"5142_CR13","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1089\/jwh.2013.4270","volume":"22","author":"JA Cauley","year":"2013","unstructured":"Cauley JA, Chlebowski RT, Wactawski-Wende J, Robbins JA, Rodabough RJ, Chen Z, Johnson KC, O\u2019Sullivan MJ, Jackson RD, Manson JE (2013) Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women\u2019s Health Initiative. J Women\u2019s Health 22(2002):915\u2013929","journal-title":"J Women\u2019s Health"},{"key":"5142_CR14","unstructured":"2015 S (2015) Stata statistical software. Texas"},{"key":"5142_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00223-009-9329-4","volume":"86","author":"M Hiligsmann","year":"2010","unstructured":"Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86:202\u2013210","journal-title":"Calcif Tissue Int"},{"key":"5142_CR16","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1007\/s00198-011-1668-0","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Cooper C, Hiligsmann M, Rabenda V, Reginster JY, Rizzoli R (2011) Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int 22:2565\u20132573","journal-title":"Osteoporos Int"},{"key":"5142_CR17","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","volume":"18","author":"JA Cramer","year":"2007","unstructured":"Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023\u20131031","journal-title":"Osteoporos Int"},{"key":"5142_CR18","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S0025-6196(11)61093-8","volume":"82","author":"P Kothawala","year":"2007","unstructured":"Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493\u20131501","journal-title":"Mayo Clin Proc"},{"key":"5142_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00198-010-1211-8","volume":"22","author":"ES Siris","year":"2011","unstructured":"Siris ES, Gehlbach S, Adachi JD, Boonen S, Chapurlat RD, Compston JE, Cooper C, Delmas P, D\u00edez-P\u00e9rez A, Hooven FH, LaCroix AZ, Netelenbos JC, Pfeilschifter J, Rossini M, Roux C, Saag KG, Sambrook P, Silverman S, Watts NB, Wyman A, Greenspan SL (2011) Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int 22:27\u201335","journal-title":"Osteoporos Int"},{"key":"5142_CR20","first-page":"3495","volume-title":"Osteoporos Int","author":"AE Litwic","year":"2017","unstructured":"Litwic AE, Compston JE, Wyman A et al (2017) Self-perception of fracture risk: what can it tell us? In: Osteoporos Int, vol 28, pp 3495\u20133500"},{"key":"5142_CR21","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/jbmr.2565","volume":"30","author":"S Jha","year":"2015","unstructured":"Jha S, Wang Z, Laucis N, Bhattacharyya T (2015) Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996-2012: an ecological analysis. J Bone Miner Res 30:2179\u20132187","journal-title":"J Bone Miner Res"},{"key":"5142_CR22","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/pds.3703","volume":"23","author":"G Peeters","year":"2014","unstructured":"Peeters G, Tett SE, Duncan EL, Mishra GD, Dobson AJ (2014) Osteoporosis medication dispensing for older Australian women from 2002 to 2010: influences of publications, guidelines, marketing activities and policy. Pharmacoepidemiol Drug Saf 23:1303\u20131311","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5142_CR23","doi-asserted-by":"crossref","unstructured":"van der Velde RY, Wyers CE, Curtis EM, Geusens PP, van den Bergh JP, de Vries F, Cooper C, van Staa TP, Harvey NC (2016) Secular trends in fracture incidence in the UK between 1990 and 2012. Osteoporos Int","DOI":"10.1007\/s00198-016-3650-3"},{"key":"5142_CR24","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1002\/jbmr.2882","volume":"31","author":"S Hawley","year":"2016","unstructured":"Hawley S, Leal J, Delmestri A, Prieto-Alhambra D, Arden NK, Cooper C, Javaid MK, Judge A (2016) Anti-osteoporosis medication prescriptions and incidence of subsequent fracture among primary hip fracture patients in England and Wales: an interrupted time-series analysis. J Bone Miner Res 31:2008\u20132015","journal-title":"J Bone Miner Res"},{"key":"5142_CR25","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136","journal-title":"Arch Osteoporos"},{"key":"5142_CR26","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1007\/s00198-013-2364-z","volume":"24","author":"M Hiligsmann","year":"2013","unstructured":"Hiligsmann M, Salas M, Hughes DA, Manias E, Gwadry-Sridhar FH, Linck P, Cowell W (2013) Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int 24:2907\u20132918","journal-title":"Osteoporos Int"},{"key":"5142_CR27","doi-asserted-by":"publisher","first-page":"e83552","DOI":"10.1371\/journal.pone.0083552","volume":"9","author":"C Salter","year":"2014","unstructured":"Salter C, McDaid L, Bhattacharya D, Holland R, Marshall T, Howe A (2014) Abandoned acid? Understanding adherence to bisphosphonate medications for the prevention of osteoporosis among older women: a qualitative longitudinal study. PLoS One 9:e83552","journal-title":"PLoS One"},{"key":"5142_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/bcp.12942","volume":"82","author":"M El Alili","year":"2016","unstructured":"El Alili M, Vrijens B, Demonceau J, Evers SM, Hiligsmann M (2016) A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence. Br J Clin Pharmacol 82:268\u2013279","journal-title":"Br J Clin Pharmacol"},{"key":"5142_CR29","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.socscimed.2011.06.030","volume":"73","author":"CI Salter","year":"2011","unstructured":"Salter CI, Howe A, McDaid L, Blacklock J, Lenaghan E, Shepstone L (2011) Risk, significance and biomedicalisation of a new population: older women\u2019s experience of osteoporosis screening. Soc Sci Med (1982) 73:808\u2013815","journal-title":"Soc Sci Med (1982)"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-05142-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-019-05142-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-05142-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T23:19:28Z","timestamp":1602371968000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-019-05142-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,12]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["5142"],"URL":"https:\/\/doi.org\/10.1007\/s00198-019-05142-z","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,12]]},"assertion":[{"value":"16 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"CC has received consultancy fees and honoraria from Amgen, Danone, Eli Lilly, GlaxoSmithKline, Medtronic, Merck, Nestl\u00e9, Novartis, Pfizer, Roche, Servier, Shire, Takeda and UCB. NH has received consultancy, lecture fees and honoraria from Alliance for Better Bone Health, Amgen, MSD, Eli Lilly, Servier, Shire, UCB, Consilient Healthcare and Internis Pharma. JK has held grants from Amgen, Lilly, Unigene and Radius Health; has received non-financial support from Medimaps, Asahi and AgNovos; and is the architect of FRAX<sup>\u00ae<\/sup>, but has no financial interest. EM has been, or currently is, an adviser or speaker for and has received research support from ActiveSignal, Amgen, AstraZeneca, Consilient Healthcare, GlaxoSmithKline, Hologic, Internis, Eli Lilly, Medtronic, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier, Synexus, Tethys, UCB and Warner Chilcott; and has received research support from I3 Innovus, International Osteoporosis Foundation and Unilever. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}